Phase
Condition
Meningococcal Infection
Treatment
Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine
Clinical Study ID
All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
The eligible population will include pregnant women and their offspring residing in the US and its territories who are exposed to MenQuadfi® during their pregnancy or within 30 days prior to their LMP, for whom the exposure is reported to the pregnancy registry.
Reports of MenQuadfi® pregnancy exposure must contain the following information:
Sufficient evidence to confirm that vaccination occurred during the pregnancy or inthe 30 days preceding the LMP;
Vaccine name (brand or generic) is provided (i.e., MenQuadfi®, Meningococcalvaccine, MenACWY conjugate vaccine), or not specified (eg, meningococcal vaccinefrom an unknown manufacturer).
Exclusion
Exclusion Criteria:
Only post-marketing spontaneous case reports will be included; reports from clinical trials will not be part of the registry.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Design
Study Description
Connect with a study center
Investigational site
Swiftwater, Pennsylvania 18370-0187
United StatesActive - Recruiting
Pennsylvania Locations
Swiftwater, Pennsylvania 18370-0187
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.